Trial · NCT03536754
Registered outcomes56
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 56
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in UPCR at Week 12 | Baseline to Week 12 | Least squared mean ratio of UPCR (Urine protein g:creatinine g) compared to baseline at Week 12 in the ITT population. ITT- Intent to treat |
| Primary | Number of Participants of Treatment-emergent AEs (TEAE), TEAEs Leading to Study Withdrawal, and Serious Adverse Events (SAEs) | Baseline to Week 12, and Week 12 to Week 24 | TEAEs leading to study withdrawal means study drug discontinuation in this endpoint. |
| Primary | Change From Baseline in Activated Partial Thromboplastin Time | Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension) | Normal Range: 23.9 - 40.0 |
| Primary | Change From Baseline in Plasma Alanine Aminotransferase | Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension) | Normal Range: 6 - 41 U/L |
| Primary | Change From Baseline in Plasma Alkaline Phosphatase | Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension) | |
| Primary | Change From Baseline in Plasma Amylase | Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension) | Normal range: 22-123 U/L |
| Primary | Change From Baseline in Plasma Aspartate Aminotransferase | Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension) | Normal range : 9-34 U/L |
| Primary | Change From Baseline in Plasma Bicarbonate | Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension) | Normal range: 21-33 mmol/L |
| Primary | Change From Baseline in Plasma Bilirubin | Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension) | Normal range: 0.1-1.10 mg/dL |
| Primary | Change From Baseline in Plasma C Reactive Protein | Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension) | Normal range: 0.0-3.0 mg/L |
| Primary | Change From Baseline in Plasma Calcium | Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension) | Normal range: 8.5-10.5 mg/dL |
| Primary | Change From Baseline in Plasma Chloride | Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension) | Normal range: 95-110 mmol/L |
| Primary | Change From Baseline in Plasma Cholesterol | Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension) | Normal range: 100-200 mg/dL |
| Primary | Change From Baseline in Plasma Creatine Kinase | Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension) | Normal range: 23-210 U/L |
| Primary | Change From Baseline in Plasma Creatinine | Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension) | Normal range: 0.62-1.44 mg/dL |
| Primary | Change From Baseline in Plasma Cystatin C | Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension) | Normal range: 0.53-0.95 mg/L |
| Primary | Change From Baseline in Plasma Direct Bilirubin | Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension) | |
| Primary | Change From Baseline in Plasma Glucose | Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension) | |
| Primary | Change From Baseline in Plasma HDL Cholesterol | Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension) | HDL -High-density lipoprotein |
| Primary | Change From Baseline in Plasma Indirect Bilirubin | Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03536754/registered